Correlation of lipoprotein(a) with the extent of coronary artery disease in patients with established coronary atherosclerosis: gender differences.

Objective: To assess the gender differences in correlation lipoprotein(a) concentration with the extent of coronary artery disease in patients with established coronary artery disease.

Patients And Methods: Blood lipids and lipoprotein(a) concentrations were measured in 351 consecutive patients (256 men and 95 women) who underwent coronary angiography between January and May 2010, and who had established coronary atherosclerosis (angiography score >1). A modified angiographic Gensini Score was used.

Correlation of lipoprotein (a) concentration with the extent of coronary artery disease in patients on lipid lowering therapy.

Objectives: Lipoprotein (a) [Lp(a)], together with other serum lipoproteins have an important role in the pathogenesis of coronary heart disease. The objective of the study was to assess the association between plasma levels of Lp(a) with the extent of angiographically defined coronary artery disease (CAD).

Patients And Methods: A total of 518 consecutive patients (66 % males) underwent coronary angiography in connection with lipids and lipoprotein determinations between 1st January and 31st May 2010.

[Deficits in lipid lowering therapy and achieving target lipid concentrations in patients with high risk of a cardiovascular event].

Lipid concentrations were analysed in 529 consecutive patients, 190 females (34%) and 339 males (66%) with mean age 66 years, at high cardiovascular risk, undergoing elective coronary angiography between 1st January and 31st May 2010. LDL-cholesterol level < 2,5 mmol/l was identified only in 36% of patients in primary prevention, LDL-cholesterol level < 2,0 mmol/l was identified only in 28% of subjects in secondary prevention of cardiovascular events. The study proves inadequate control of dyslipidaemia in patients at high cardiovascular risk.

Temporary (short-term) percutaneous left ventricular assist device (Tandem Heart) in a patient with STEMI, multivessel coronary artery disease, cardiogenic shock and severe peripheral artery disease.

Cardiogenic shock remains the leading cause of mortality among patients admitted for acute myocardial infarction (AMI). Percutaneous left ventricular assist devices (pVAD) represent one possible means of supporting these critically ill patients during interventional procedures. Tandem Heart is one such pVAD, which uses transseptal cannulation and a paracorporal centrifugal pump to maintain active circulation to the descending aorta.